IPFA/BCA 3rd Global Symposium
on the Future for Blood and Plasma Donations
11 – 12 September 2017
The Ritz-Carlton, Buckhead, Atlanta, GA, USA

Theme:
"Exploring the potential for donors and Blood Centers to increase their contribution to the needs of patients for both blood and plasma derived medicinal products"

Program as per 10 May 2017

Day I – Monday 11 September 2017

09:00 hrs Session 1: OPENING SESSION

- Welcome and Introduction
- Presentation by Blood Assurance
- Formal opening by Centers for Disease Control
- Key-Note "Setting the scene"

10:15 hrs COFFEE BREAK

10:45 hrs Session 2: WHY THE NEED FOR INCREASED PLASMA PRODUCTION? – PATIENT PERSPECTIVE.

- Value of immunoglobuline products for GBS / CIDP patients
- Living with von Willebrand disease
- Prospects for the future use of immunoglobulin products
- Clinical use of plasma products including impact of new developments in the use of Plasma-derived medicinal products, SIPPET study
- Panel discussion

12:15 hrs LUNCH

13:45 hrs Session 3: STRATEGIC APPROACHES TO SECURITY OF SUPPLY

- Evolution to Strategic Independence, a Canadian perspective
- Towards a Sustainable Blood Supply in the US - View of different stakeholders; including presentation from RAND
- Blood Supply Sustainability – The Next Chapter
- Panel Discussion

15:15 hrs COFFEE BREAK

15:45 hrs Session 4: PRACTICAL, OPERATIONAL APPROACHES FOR CHANGING A BLOOD CENTRE INTO A BLOOD/PLASMA COLLECTION CENTRE

- Experience BloodSource
- Experience LifeServe Blood Center
- Experience Blood Assurance
- Panel discussion

17:15 hrs END OF DAY I

18.15 hrs DEPARTURE FOR SYMPOSIUM RECEPTION AT THE ATLANTA HISTORY CENTRE

<u>Day II – Tuesday 12 September 2017</u>

08:30 hrs Session 5: MANUFACTURERS' SESSION
Max. of 5 x 20 minute presentations

- Abbott
- QualTex Laboratories

10:30 hrs COFFEE BREAK

ATLANTA

11:00 hrs Session 6: TTIs AND MICROBIOLOGICAL RISKS

- FDA Transfusion Transmitted Infections Monitoring System (TTIMS)
- Impact of MSM policy changes in multiple countries and planned Canadian studies of individual donor risk assessments
- Recent analyses of the ID safety of Source Plasma vs recovered plasma from US donors
- Panel discussion

12:30 hrs LUNCH

14:00 hrs Session 7: REGULATORY CONVERGENCE

- US and EU view on GMP inspections => Potential Future Mutual Agreement for Inspections
- Regulatory Constraints for Recovered plasma as source for plasma for fractionation (would include freezing and expiration date)
- Donor safety, including EU requirements – volumes, frequency, testing…
- Panel Discussion

15:30 hrs Session 8: A VIEW ON THE FUTURE

- Plasma Based Medicines – A Distributors' Perspective
- The market from a Hospital GPO perspective